JAGX · Jaguar Health, Inc. · Executive Compensation
$2.63
-0.19 (-6.74%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements. While management believes this infusion improves our liquidity, it does not fully alleviate the conditions that raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.81M
Shares
689,107
Volume · Oct 20
266.67K
Avg daily vol (3 sessions)
557.76K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anula Jayasuriya | Class III director | Appointed | 2022-07-06 |
| Greg J. Divis | member of the Board | Resigned | 2022-07-06 |
Leadership
- Lisa A. Conte CEO, Board Member
- James J. Bochnowski Chairman
- Carol Lizak CFO, Chief Accounting Officer
- Carol R. Lizak CFO, Chief Accounting Officer
- Jonathan S. Wolin General Counsel
- Anula Jayasuriya Board Member
- John Micek III Board Member
- Jonathan B. Siegel Board Member